Disputes and Challenges of Immune Checkpoint Inhibitors in Gastrointestinal Cancers PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Disputes and Challenges of Immune Checkpoint Inhibitors in Gastrointestinal Cancers PDF full book. Access full book title Disputes and Challenges of Immune Checkpoint Inhibitors in Gastrointestinal Cancers by Hongwei Yao. Download full books in PDF and EPUB format.
Author: Hongwei Yao
Publisher: Frontiers Media SA
ISBN: 2832549101
Category : Science
Languages : en
Pages : 134
Get Book
Book Description
Recently, immune checkpoint inhibitors (ICIs) have received a lot of attention to treat gastrointestinal cancers. Compared with traditional treatments, immunotherapy can kill cancer cells by activating the antitumor immunity, the specific recognition of cancer antigens preventing normal cells from being attacked. However, the application of ICIs is accompanied by a series of specific toxic reactions caused by the functional stimulation of the immune system, which are called immune-related adverse events (irAEs). Early identification and timely intervention to handle irAEs are usually required to maximize the therapeutic effect of ICIs. In addition, related surgical complications after neoadjuvant immunotherapy is increasingly reported. Thus, although immunotherapy has shown obvious advantages in the clinical treatment of gastrointestinal cancers, the safety and potential risks of such treatment have to be considered. Many clinical studies have shown that cancer patients receiving neoadjuvant immunotherapy experience different degrees of immune-inflammatory reaction, immune disorders, immune-related pneumonia, and other adverse events. In addition, some patients suffering from irAEs during the treatment have to face a delayed operation or even lose the opportunity to be operated. Finally, because the clinical imaging manifestations of immunotherapy are complex and diverse, the imaging evaluation criteria have so far not been standardized. The aim of this Research Topic is to report disputes and challenges of immune checkpoint inhibitors in gastrointestinal cancers. We welcome original research articles, Review articles, Mini Reviews, and Case reports. Preferred topics include but are not limited to the following: • Timely discovery of immune-related adverse events during immunotherapy • Identification and differentiation between immune-related adverse events and adverse drug events • Treatment and drug withdrawal timing upon immune-related adverse events • Management of related surgical complications after neoadjuvant immunotherapy • Imaging evaluation criteria or methods of immunotherapy efficacy
Author: Hongwei Yao
Publisher: Frontiers Media SA
ISBN: 2832549101
Category : Science
Languages : en
Pages : 134
Get Book
Book Description
Recently, immune checkpoint inhibitors (ICIs) have received a lot of attention to treat gastrointestinal cancers. Compared with traditional treatments, immunotherapy can kill cancer cells by activating the antitumor immunity, the specific recognition of cancer antigens preventing normal cells from being attacked. However, the application of ICIs is accompanied by a series of specific toxic reactions caused by the functional stimulation of the immune system, which are called immune-related adverse events (irAEs). Early identification and timely intervention to handle irAEs are usually required to maximize the therapeutic effect of ICIs. In addition, related surgical complications after neoadjuvant immunotherapy is increasingly reported. Thus, although immunotherapy has shown obvious advantages in the clinical treatment of gastrointestinal cancers, the safety and potential risks of such treatment have to be considered. Many clinical studies have shown that cancer patients receiving neoadjuvant immunotherapy experience different degrees of immune-inflammatory reaction, immune disorders, immune-related pneumonia, and other adverse events. In addition, some patients suffering from irAEs during the treatment have to face a delayed operation or even lose the opportunity to be operated. Finally, because the clinical imaging manifestations of immunotherapy are complex and diverse, the imaging evaluation criteria have so far not been standardized. The aim of this Research Topic is to report disputes and challenges of immune checkpoint inhibitors in gastrointestinal cancers. We welcome original research articles, Review articles, Mini Reviews, and Case reports. Preferred topics include but are not limited to the following: • Timely discovery of immune-related adverse events during immunotherapy • Identification and differentiation between immune-related adverse events and adverse drug events • Treatment and drug withdrawal timing upon immune-related adverse events • Management of related surgical complications after neoadjuvant immunotherapy • Imaging evaluation criteria or methods of immunotherapy efficacy
Author: Ramakrishna Vadde
Publisher: Springer Nature
ISBN: 9811564876
Category : Medical
Languages : en
Pages : 257
Get Book
Book Description
This book reviews current immunotherapeutic strategies for gastrointestinal (GI) malignancies, including immune composition, immune checkpoint inhibitors, cell therapy, and peptide vaccines used to protect against esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers. It also discusses the current challenges of using immunotherapy for the treatment of gastrointestinal malignancies. The book reviews highly sensitive and specific immunomarkers for the detection of GI malignancies, and examines therapeutic vaccines and the major cytokines involved in GI immunotherapy, as well as their basic biology and clinical applications. In closing, the book explores various aspects of computational biology for the detection and treatment of GI malignancies.
Author: Fumito Ito
Publisher: Elsevier Health Sciences
ISBN: 0323549500
Category : Medical
Languages : en
Pages : 400
Get Book
Book Description
Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. Helps you translate current research and literature into practical information for daily practice. Presents information logically organized by disease site. Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. Consolidates today’s available information on this timely topic into one convenient resource.
Author: Marc S. Ernstoff, MD
Publisher: Springer Publishing Company
ISBN: 0826172156
Category : Medical
Languages : en
Pages : 250
Get Book
Book Description
The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer
Author: Tim F. Greten
Publisher: Springer
ISBN: 3319649582
Category : Medical
Languages : en
Pages : 167
Get Book
Book Description
In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
Author: Linda M. Liau
Publisher: Springer Science & Business Media
ISBN: 1592590357
Category : Medical
Languages : en
Pages : 369
Get Book
Book Description
An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.
Author: Peter L. Stern
Publisher: Cambridge University Press
ISBN: 9780521622639
Category : Medical
Languages : en
Pages : 304
Get Book
Book Description
Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments.
Author: Allan B. Wolfson
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 248
Get Book
Book Description
Author: Jie Xu
Publisher: Springer Nature
ISBN: 9811532664
Category : Medical
Languages : en
Pages : 657
Get Book
Book Description
This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
Author: Luciano Adorini
Publisher: S. Karger AG (Switzerland)
ISBN:
Category : Medical
Languages : en
Pages : 184
Get Book
Book Description
